Experienced in Hepatitis B

Taner Yıldırmak

Prof. Dr. Cemil Tascioglu City Hospital
Istanbul, TR 
Experienced in Hepatitis B
Prof. Dr. Cemil Tascioglu City Hospital
Istanbul, TR 
OverviewLocationsClinical Research

Overview

Taner Yıldırmak practices in Istanbul, Turkey. Mr. Yıldırmak is rated as an Experienced expert by MediFind in the treatment of Hepatitis B. His top areas of expertise are Febrile Neutropenia, HIV/AIDS, Agranulocytosis, and Hepatitis.

His clinical research consists of co-authoring 27 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Hepatitis B.

Gender
Male

Locations

Prof. Dr. Cemil Tascioglu City Hospital
Istanbul, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drug: CoronaVac Vaccine
Study Phase: Phase 3
Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial
Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial
Enrollment Status: Completed
Publish Date: February 29, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

27 Total Publications

Prevalence of Cardiovascular Disease and Comparison of Risk Category Predictions of Systemic Coronary Risk Evaluation Score-2 and 4 Other Cardiovascular Disease Risk Assessment Tools Among People Living with Human Immunodefficiency Virus in Türkiye.
Prevalence of Cardiovascular Disease and Comparison of Risk Category Predictions of Systemic Coronary Risk Evaluation Score-2 and 4 Other Cardiovascular Disease Risk Assessment Tools Among People Living with Human Immunodefficiency Virus in Türkiye.
Journal: Anatolian journal of cardiology
Published: October 18, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Yıldırmak's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile